Wednesday, December 21, 2016

BRIEF-Merrimack stops Phase 2 Hermione trial of MM-302 in Her2-positive metastatic breast cancer patients

* Merrimack Pharmaceuticals Inc says now plans to provide

results of ongoing strategic pipeline review in January

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)